智通财经网·2025-09-09 07:39Group 1 - Alibaba Health (00241) shares increased by 10%, reaching a high of 7.18 HKD, the highest since January 2023, with a trading volume of 2.036 billion HKD [1] - HSBC Global Research anticipates that health products will continue to be the fastest-growing category for Alibaba Health, supported by its robust platform ecosystem [1] - The focus on first-party sales (1P) profitability may limit sales growth in pharmaceuticals, but the shift of offline traffic to online due to tighter social insurance claims is expected to benefit Alibaba Health from strong demand for innovative drugs [1] Group 2 - The unexpected sales momentum of innovative drugs may provide upward potential for revenue and net profit forecasts for Alibaba Health [1] - The National Medical Products Administration is drafting a compliance guideline for online prescription drug sales to enhance compliance awareness and capabilities among stakeholders [1] - The guideline emphasizes that companies must fulfill their responsibilities for drug safety and continuously improve their quality management systems and compliance management [1]